JP2014530185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530185A5 JP2014530185A5 JP2014530332A JP2014530332A JP2014530185A5 JP 2014530185 A5 JP2014530185 A5 JP 2014530185A5 JP 2014530332 A JP2014530332 A JP 2014530332A JP 2014530332 A JP2014530332 A JP 2014530332A JP 2014530185 A5 JP2014530185 A5 JP 2014530185A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- drug
- core
- particles
- active layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 87
- 239000003814 drug Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 41
- 239000003349 gelling agent Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 238000004090 dissolution Methods 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 22
- 230000002496 gastric effect Effects 0.000 claims description 22
- 238000000338 in vitro Methods 0.000 claims description 22
- 239000006186 oral dosage form Substances 0.000 claims description 22
- 230000004888 barrier function Effects 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 229960002085 oxycodone Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 239000003401 opiate antagonist Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 2
- 229960000240 hydrocodone Drugs 0.000 claims description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 2
- 229960001410 hydromorphone Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 229960005118 oxymorphone Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000003204 tranquilizing agent Substances 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 229940127450 Opioid Agonists Drugs 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535758P | 2011-09-16 | 2011-09-16 | |
| US61/535,758 | 2011-09-16 | ||
| PCT/IB2012/001916 WO2013038268A1 (en) | 2011-09-16 | 2012-09-14 | Tamper resistant immediate release formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530185A JP2014530185A (ja) | 2014-11-17 |
| JP2014530185A5 true JP2014530185A5 (cg-RX-API-DMAC7.html) | 2015-10-08 |
| JP6138798B2 JP6138798B2 (ja) | 2017-05-31 |
Family
ID=48577967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530332A Active JP6138798B2 (ja) | 2011-09-16 | 2012-09-14 | 不正改変抵抗性即時放出性製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140294947A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3078370B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6138798B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012310251B2 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2583132T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL231482A (cg-RX-API-DMAC7.html) |
| MX (1) | MX347961B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013038268A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| NZ704011A (en) | 2012-07-06 | 2016-04-29 | Egalet Ltd | Abuse deterrent pharmaceutical compositions for controlled release |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
| WO2019070581A1 (en) * | 2017-10-02 | 2019-04-11 | Purdue Pharma L.P | PHARMACEUTICAL COMPOSITIONS COMPRISING GELIFYING AGENT COMPOSITIONS |
| WO2019126125A1 (en) | 2017-12-20 | 2019-06-27 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| DE60319252T2 (de) * | 2002-09-21 | 2009-03-05 | Zhang, Shuyi | Formulierung von acetaminophen und tramadol mit verzögerter freisetzung |
| MXPA06004700A (es) * | 2003-10-31 | 2006-07-05 | Hexal Ag | Formulacion conteniendo agente farmaceutico comprendiendo un recubrimiento. |
| PT1691892E (pt) * | 2003-12-09 | 2007-05-31 | Euro Celtique Sa | Forma posológica co-extrusada inviolável que contém um componente activo e um componente de acção contrária e um processo para a sua fabricação |
| TWI365880B (en) | 2004-03-30 | 2012-06-11 | Euro Celtique Sa | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp |
| US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| US8652529B2 (en) * | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| DK2526932T3 (en) * | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| PL2187873T3 (pl) * | 2007-08-13 | 2019-01-31 | Abuse Deterrent Pharmaceutical Llc | Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania |
| WO2009025859A1 (en) * | 2007-08-21 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Paliperidone sustained release formulation |
| BRPI0913425A2 (pt) * | 2008-06-02 | 2015-11-24 | Reddys Lab Ltd Dr | formulações de niacina com liberação modificada |
| PH12013501345A1 (en) * | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| JP2014524925A (ja) * | 2011-07-29 | 2014-09-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
-
2012
- 2012-09-14 ES ES12772421.9T patent/ES2583132T3/es active Active
- 2012-09-14 EP EP16167881.8A patent/EP3078370B1/en active Active
- 2012-09-14 MX MX2014003192A patent/MX347961B/es active IP Right Grant
- 2012-09-14 EP EP12772421.9A patent/EP2755638B1/en active Active
- 2012-09-14 JP JP2014530332A patent/JP6138798B2/ja active Active
- 2012-09-14 ES ES16167881T patent/ES2703688T3/es active Active
- 2012-09-14 AU AU2012310251A patent/AU2012310251B2/en active Active
- 2012-09-14 US US14/344,271 patent/US20140294947A1/en not_active Abandoned
- 2012-09-14 WO PCT/IB2012/001916 patent/WO2013038268A1/en not_active Ceased
-
2014
- 2014-03-12 IL IL231482A patent/IL231482A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530185A5 (cg-RX-API-DMAC7.html) | ||
| JP2014526497A5 (cg-RX-API-DMAC7.html) | ||
| JP6509287B2 (ja) | 不正使用抵抗性の即時放出製剤 | |
| JP6138798B2 (ja) | 不正改変抵抗性即時放出性製剤 | |
| KR101820475B1 (ko) | 변조 내성 약제학적 제형 | |
| ES2609695T3 (es) | Comprimidos de oxicodona resistentes al aplastamiento destinados a evitar el uso incorrecto involuntario y la desviación ilícita de uso | |
| ES2851175T3 (es) | Formulaciones farmacéuticas resistentes a manipulación | |
| ES2569925T3 (es) | Métodos y composiciones de disuasión del abuso | |
| JP2015511953A5 (cg-RX-API-DMAC7.html) | ||
| JP6110384B2 (ja) | 不正改変抵抗性医薬製剤 | |
| ES2887104T3 (es) | Comprimidos sublinguales resistentes al abuso que comprenden buprenorfina y naloxona | |
| US20110166171A1 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| BR112014024382B1 (pt) | Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação | |
| PT1448235E (pt) | Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno. | |
| ES2877058T3 (es) | Composiciones farmacéuticas resistentes al abuso | |
| EP2606879A1 (en) | Multiple unit pellet tablet formulation comprising an opioid | |
| JP2014530250A (ja) | 安定化されたエペリゾン医薬造成物及びそれを含有する徐放性製剤 | |
| CN106714782A (zh) | 具有滥用遏制性质的药物组合物 | |
| CA2847613A1 (en) | Tamper resistant immediate release formulations | |
| CN102920707A (zh) | 一种复方抗结核制剂的制备工艺 | |
| Jana et al. | Ondansetron: A selective 5HT3 receptor antagonist and it advances in drug delivery system | |
| HK40009174A (en) | Tamper resistant immediate release formulations | |
| CN104306345A (zh) | 一种布南色林的口服缓释制剂 | |
| KR20200097685A (ko) | 약학 수지산염 조성물 및 그 제조 및 사용 방법 |